These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 33827905)

  • 1. Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
    Banchereau R; Chitre AS; Scherl A; Wu TD; Patil NS; de Almeida P; Kadel Iii EE; Madireddi S; Au-Yeung A; Takahashi C; Chen YJ; Modrusan Z; McBride J; Nersesian R; El-Gabry EA; Robida MD; Hung JC; Kowanetz M; Zou W; McCleland M; Caplazi P; Eshgi ST; Koeppen H; Hegde PS; Mellman I; Mathews WR; Powles T; Mariathasan S; Grogan J; O'Gorman WE
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD103
    Corgnac S; Malenica I; Mezquita L; Auclin E; Voilin E; Kacher J; Halse H; Grynszpan L; Signolle N; Dayris T; Leclerc M; Droin N; de Montpréville V; Mercier O; Validire P; Scoazec JY; Massard C; Chouaib S; Planchard D; Adam J; Besse B; Mami-Chouaib F
    Cell Rep Med; 2020 Oct; 1(7):100127. PubMed ID: 33205076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13
    Hu C; You W; Kong D; Huang Y; Lu J; Zhao M; Jin Y; Peng R; Hua D; Kuang DM; Chen Y
    Gastroenterology; 2024 Jun; 166(6):1069-1084. PubMed ID: 38445519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma.
    Lai C; Coltart G; Shapanis A; Healy C; Alabdulkareem A; Selvendran S; Theaker J; Sommerlad M; Rose-Zerilli M; Al-Shamkhani A; Healy E
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
    Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
    Front Immunol; 2020; 11():577. PubMed ID: 32391001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Emerging Role of CD8
    Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
    Front Immunol; 2018; 9():1904. PubMed ID: 30158938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
    Shimada Y; Matsubayashi J; Kudo Y; Maehara S; Takeuchi S; Hagiwara M; Kakihana M; Ohira T; Nagao T; Ikeda N
    Sci Rep; 2021 Apr; 11(1):7830. PubMed ID: 33837261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty Acid Oxidation Controls CD8
    Lin R; Zhang H; Yuan Y; He Q; Zhou J; Li S; Sun Y; Li DY; Qiu HB; Wang W; Zhuang Z; Chen B; Huang Y; Liu C; Wang Y; Cai S; Ke Z; He W
    Cancer Immunol Res; 2020 Apr; 8(4):479-492. PubMed ID: 32075801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
    Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
    Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of CD103
    Han L; Gao QL; Zhou XM; Shi C; Chen GY; Song YP; Yao YJ; Zhao YM; Wen XY; Liu SL; Qi YM; Gao YF
    Cancer Immunol Immunother; 2020 Aug; 69(8):1493-1504. PubMed ID: 32285170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
    Shimoda Y; Yoshida T; Shirasawa M; Mizuno T; Jo H; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y; Motoi N
    Anticancer Res; 2021 Nov; 41(11):5739-5747. PubMed ID: 34732447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
    Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Nojima Y; Shimizu K; Saisho S; Maeda AI; Kurosaki T; Kurose K; Oga T; Oka M; Nakata M
    Anticancer Res; 2021 Nov; 41(11):5469-5475. PubMed ID: 34732416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 19. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers.
    Wang G; Chai Q; Xiao Y; Peng W; Teng M; Wang J; Lin H; Su X; Wu L
    Front Immunol; 2020; 11():607416. PubMed ID: 33584678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.